Experience using temozolomide in the treatment of aggressive pituitary adenomas
Open Access
- 24 January 2025
- journal article
- Published by "MedINK" Publishing House in Russian journal of neurosurgery
- Vol. 26 (4) , 54-64
Abstract
Background. The term “aggressive pituitary adenoma” arose as a result of transforming the term “atypical pituitary adenoma”, which was used in WHO classification for pituitary adenomas with specifications of higher labeling index Ki-67 (≥3 %) and increased number of mitoses with expression of the p53 proteins. However, not all tumors with these features were aggressive, and currently, according to the European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumors and carcinomas (2018), aggressive pituitary tumors are labeled as tumors that have invasive and unusually rapid or clinically significant growth which occurs despite the use of standard treatment protocols (pharmacological, surgical and radiation). Till date, there are numerous papers in literature describing various schemes and indications for the use of temozolomide. The efficiency of ongoing therapy, according to different authors, varies from 29 to 81 %, with an average effectiveness ranging between 40–45 %. Aim. To present our own experience of using temozolomide in the treatment of patients with aggressive pituitary tumors. Materials and methods. Three patients were included in the study, one male (45 years old) and 2 females (61 and 29 years old). All three patients included in the study first underwent surgical resection followed by radiation therapy if no response / hormonal activity didn’t resume. The decision to start temozolomide protocol was held by concerned medical commission under supervision of local ethical committee. Results. All patients responded well to temozolomide therapy with decrease in the size of tumor and decrease in levels of prolactin in cases of prolactinoma. Conclusion. The most important step in treating patients with aggressive pituitary adenomas is their early diagnosis, which could be possible only if the specific identifying markers of aggressiveness were found, which unfortunately are not found yet.Keywords
This publication has 31 references indexed in Scilit:
- How effective is temozolomide for treating pituitary tumours and when should it be used?Pituitary, 2016
- Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinomaPituitary, 2016
- Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomasJournal of Neuro-Oncology, 2015
- Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reportsNeuro-Oncology Practice, 2015
- A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-upActa Neuropathologica, 2013
- Prevalence and incidence of pituitary adenomas: a population based study in MaltaPituitary, 2012
- Prevalence and incidence of pituitary adenomasAnnales d'Endocrinologie, 2012
- Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findingsHuman Pathology, 2007
- Antitumour effects of temozolomide in a man with a large, invasive prolactin‐producing pituitary neoplasmClinical Endocrinology, 2006
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005